Cardio‐Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies

09 Jun 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. Background. Patients with malignancies were commonly excluded from prior heart failure (HF) trials resulting in limited data regarding the outcomes of patients with HF accompanied by concomitant malignancies.
The study sought to assess the prevalence and prognostic impact of malignancies in patients with HF and HF with mildly reduced ejection fraction. Methods. Consecutive patients hospitalized with HF with mildly reduced ejection fraction were retrospectively included at 1 institution from 2016 to 2022.
The prognosis of patients with malignancies was investigated regarding the primary end point all‐cause mortality at 30 months (median follow‐up). The key secondary end point was rehospitalization for worsening HF.Results. Among 2184 patients with HF with mildly reduced ejection fraction, 15.3% (n=335) suffered from concomitant malignancies.
In patients with active malignancies (n=257), most patients had solid (n=175) followed by hematological malignancies (n=73) (both: n=9), whereas cancer‐therapy HF was observed in 3.9%. Patients with malignancies had lower rates of ischemic cardiomyopathy and were less commonly treated with beta blockers, renin‐angiotensin aldosterone antagonists, and statins.

Clinical Editorial

Summary

Journal of the American Heart Association published a clinical update in Cardiology on 09 Jun 2026.

The item focuses on Cardio‐Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.

Review the original article for the full source wording and details.